WO2008146753A1 - 脳梗塞治療剤 - Google Patents
脳梗塞治療剤 Download PDFInfo
- Publication number
- WO2008146753A1 WO2008146753A1 PCT/JP2008/059582 JP2008059582W WO2008146753A1 WO 2008146753 A1 WO2008146753 A1 WO 2008146753A1 JP 2008059582 W JP2008059582 W JP 2008059582W WO 2008146753 A1 WO2008146753 A1 WO 2008146753A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- therapeutic agent
- cerebral infarction
- novel therapeutic
- brain
- mcp
- Prior art date
Links
- 206010008118 cerebral infarction Diseases 0.000 title abstract 3
- 208000026106 cerebrovascular disease Diseases 0.000 title abstract 3
- 239000003814 drug Substances 0.000 title abstract 3
- 229940124597 therapeutic agent Drugs 0.000 title abstract 3
- -1 piperazine compound Chemical class 0.000 abstract 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 abstract 1
- 102100021943 C-C motif chemokine 2 Human genes 0.000 abstract 1
- 101710155857 C-C motif chemokine 2 Proteins 0.000 abstract 1
- 102000019034 Chemokines Human genes 0.000 abstract 1
- 108010012236 Chemokines Proteins 0.000 abstract 1
- 102000004127 Cytokines Human genes 0.000 abstract 1
- 108090000695 Cytokines Proteins 0.000 abstract 1
- 108090001005 Interleukin-6 Proteins 0.000 abstract 1
- 208000008457 Neurologic Manifestations Diseases 0.000 abstract 1
- 206010060860 Neurological symptom Diseases 0.000 abstract 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 abstract 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 210000004556 brain Anatomy 0.000 abstract 1
- 208000029028 brain injury Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- GLUUGHFHXGJENI-UHFFFAOYSA-N diethylenediamine Natural products C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/18—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Priority Applications (12)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES08764628T ES2405542T3 (es) | 2007-05-24 | 2008-05-23 | Agente terapéutico para el infarto cerebral |
AU2008255885A AU2008255885A1 (en) | 2007-05-24 | 2008-05-23 | Therapeutic agent for cerebral infarction |
US12/601,609 US8835631B2 (en) | 2007-05-24 | 2008-05-23 | Therapeutic agent for cerebral infarction |
CN200880017326A CN101679367A (zh) | 2007-05-24 | 2008-05-23 | 脑梗塞治疗药剂 |
CA 2687942 CA2687942A1 (en) | 2007-05-24 | 2008-05-23 | Therapeutic agent for cerebral infarction |
EP20080764628 EP2154135B1 (en) | 2007-05-24 | 2008-05-23 | Therapeutic agent for cerebral infarction |
BRPI0811222 BRPI0811222A2 (pt) | 2007-05-24 | 2008-05-23 | Agente terapêutico para infarto cerebral. |
JP2009516304A JP5366803B2 (ja) | 2007-05-24 | 2008-05-23 | 脳梗塞治療剤 |
US14/457,173 US20140350249A1 (en) | 2007-05-24 | 2014-08-12 | Therapeutic agent for cerebral infarction |
US14/457,283 US20140350250A1 (en) | 2007-05-24 | 2014-08-12 | Therapeutic agent for cerebral infarction |
US14/575,489 US20150104483A1 (en) | 2007-05-24 | 2014-12-18 | Therapeutic agent for cerebral infarction |
US14/575,599 US9233969B2 (en) | 2007-05-24 | 2014-12-18 | Therapeutic agent for cerebral infarction |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2007-137504 | 2007-05-24 | ||
JP2007137504 | 2007-05-24 |
Related Child Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/601,609 A-371-Of-International US8835631B2 (en) | 2007-05-24 | 2008-05-23 | Therapeutic agent for cerebral infarction |
US14/457,173 Continuation US20140350249A1 (en) | 2007-05-24 | 2014-08-12 | Therapeutic agent for cerebral infarction |
US14/457,283 Division US20140350250A1 (en) | 2007-05-24 | 2014-08-12 | Therapeutic agent for cerebral infarction |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2008146753A1 true WO2008146753A1 (ja) | 2008-12-04 |
Family
ID=40075000
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2008/059582 WO2008146753A1 (ja) | 2007-05-24 | 2008-05-23 | 脳梗塞治療剤 |
Country Status (11)
Country | Link |
---|---|
US (5) | US8835631B2 (ja) |
EP (2) | EP2532658A1 (ja) |
JP (1) | JP5366803B2 (ja) |
KR (1) | KR20100022080A (ja) |
CN (1) | CN101679367A (ja) |
AU (1) | AU2008255885A1 (ja) |
BR (1) | BRPI0811222A2 (ja) |
CA (1) | CA2687942A1 (ja) |
ES (1) | ES2405542T3 (ja) |
RU (1) | RU2009148049A (ja) |
WO (1) | WO2008146753A1 (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2011524409A (ja) * | 2008-06-16 | 2011-09-01 | サノフイ−アベンテイス | Tnfの調節活性を有するフェニル−アルキルピペラジン |
US8609672B2 (en) | 2010-08-27 | 2013-12-17 | University Of The Pacific | Piperazinylpyrimidine analogues as protein kinase inhibitors |
WO2014119438A1 (ja) * | 2013-01-29 | 2014-08-07 | 国立大学法人大阪大学 | 梗塞性疾患の予防又は治療用医薬 |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2008255885A1 (en) * | 2007-05-24 | 2008-12-04 | Mitsubishi Tanabe Pharma Corporation | Therapeutic agent for cerebral infarction |
CN106977500A (zh) * | 2017-04-17 | 2017-07-25 | 牡丹江医学院 | 一种用于治疗脑梗塞的药物及其制备方法 |
ES2822399B2 (es) | 2019-10-31 | 2022-02-16 | Univ Murcia | Dispositivo de recogida de fluido uterino in vivo |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999019301A1 (fr) | 1997-10-14 | 1999-04-22 | Yoshitomi Pharmaceutical Industries, Ltd. | Composes de piperazine et utilisation medicale desdits composes |
JP2005511698A (ja) * | 2001-11-30 | 2005-04-28 | シェーリング コーポレイション | アデノシンA2aレセプターアンタゴニスト |
WO2005103013A1 (ja) | 2004-04-27 | 2005-11-03 | Mitsubishi Pharma Corporation | 非ウイルス性肝炎治療薬 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005110982A2 (en) * | 2004-04-07 | 2005-11-24 | Neurogen Corporation | Substituted 1-benzyl-4-substituted piperazine analogues |
SG166829A1 (en) * | 2005-11-08 | 2010-12-29 | Ranbaxy Lab Ltd | Process for (3r, 5r)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4- [(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3, 5-dihydroxy-heptanoic acid hemi calcium salt |
AU2008255885A1 (en) | 2007-05-24 | 2008-12-04 | Mitsubishi Tanabe Pharma Corporation | Therapeutic agent for cerebral infarction |
-
2008
- 2008-05-23 AU AU2008255885A patent/AU2008255885A1/en not_active Abandoned
- 2008-05-23 WO PCT/JP2008/059582 patent/WO2008146753A1/ja active Application Filing
- 2008-05-23 CN CN200880017326A patent/CN101679367A/zh active Pending
- 2008-05-23 JP JP2009516304A patent/JP5366803B2/ja not_active Expired - Fee Related
- 2008-05-23 ES ES08764628T patent/ES2405542T3/es active Active
- 2008-05-23 US US12/601,609 patent/US8835631B2/en not_active Expired - Fee Related
- 2008-05-23 EP EP20120182964 patent/EP2532658A1/en not_active Withdrawn
- 2008-05-23 KR KR20097026774A patent/KR20100022080A/ko not_active Application Discontinuation
- 2008-05-23 EP EP20080764628 patent/EP2154135B1/en not_active Not-in-force
- 2008-05-23 RU RU2009148049/04A patent/RU2009148049A/ru not_active Application Discontinuation
- 2008-05-23 BR BRPI0811222 patent/BRPI0811222A2/pt not_active IP Right Cessation
- 2008-05-23 CA CA 2687942 patent/CA2687942A1/en not_active Abandoned
-
2014
- 2014-08-12 US US14/457,283 patent/US20140350250A1/en not_active Abandoned
- 2014-08-12 US US14/457,173 patent/US20140350249A1/en not_active Abandoned
- 2014-12-18 US US14/575,489 patent/US20150104483A1/en not_active Abandoned
- 2014-12-18 US US14/575,599 patent/US9233969B2/en not_active Expired - Fee Related
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999019301A1 (fr) | 1997-10-14 | 1999-04-22 | Yoshitomi Pharmaceutical Industries, Ltd. | Composes de piperazine et utilisation medicale desdits composes |
JP2005511698A (ja) * | 2001-11-30 | 2005-04-28 | シェーリング コーポレイション | アデノシンA2aレセプターアンタゴニスト |
WO2005103013A1 (ja) | 2004-04-27 | 2005-11-03 | Mitsubishi Pharma Corporation | 非ウイルス性肝炎治療薬 |
Non-Patent Citations (16)
Title |
---|
BARONE F.C. ET AL.: "Tumor necrosis factor-alpha: a mediator of focal ischemic brain injury", STORKE, vol. 28, no. 6, 1997, pages 1233 - 1244, XP008123609 * |
BARONE, F.C. ET AL., STROKE, vol. 28, 1997, pages 1223 - 1244 |
BETZ, A.L. ET AL., J. CEREB. BLOOD FLOW METAB., vol. 15, 1995, pages 547 - 551 |
DIRNAGL, U. ET AL., TRENDS. NEUROSCI., vol. 22, 1999, pages 391 - 397 |
DIRNAGL, U. ET AL., TRENDS. NEUROSCI., vol. 26, 2003, pages 248 - 254 |
EMSLEY, H.C.A. ET AL., J. NEUROL. NEUROSURG. PSYCH., vol. 76, 2005, pages 1366 - 1372 |
FUKUDA, T. ET AL., J. PHARMACY PHARMACOL., vol. 57, 2005, pages 1 - 6 |
FURUICHI, Y ET AL., J. CEREB. BLOOD FLOW METAB., vol. 23, 2003, pages 1183 - 1194 |
HANANO T. ET AL.: "Novel DMARDs on the basis of a new concept of dual cytokine regulation, TNF-alpha suppression and IL-10 augmentation", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 10, no. 9, 2000, pages 881 - 884, XP004199034 * |
HISADOME, M. ET AL., EUR. J. PHARMACOL., vol. 497, 2004, pages 351 - 359 |
J. ORG. CHEM., vol. 67, 2002, pages 3965 - 3968 |
KOIZUMI, J. ET AL., JPN. J. STROKE, vol. 8, 1986, pages 1 - 8 |
ORGANIC LETTERS, vol. 5, no. 5, 2003, pages 753 - 755 |
See also references of EP2154135A4 * |
WANG, X. ET AL., MOLECULAR PHARMACOLOGY, vol. 65, 2004, pages 890 - 896 |
YAMAZAKI, Y. ET AL., STROKE, vol. 26, 1995, pages 676 - 681 |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2011524409A (ja) * | 2008-06-16 | 2011-09-01 | サノフイ−アベンテイス | Tnfの調節活性を有するフェニル−アルキルピペラジン |
US8609672B2 (en) | 2010-08-27 | 2013-12-17 | University Of The Pacific | Piperazinylpyrimidine analogues as protein kinase inhibitors |
WO2014119438A1 (ja) * | 2013-01-29 | 2014-08-07 | 国立大学法人大阪大学 | 梗塞性疾患の予防又は治療用医薬 |
Also Published As
Publication number | Publication date |
---|---|
KR20100022080A (ko) | 2010-02-26 |
US20140350249A1 (en) | 2014-11-27 |
CN101679367A (zh) | 2010-03-24 |
US20100179157A1 (en) | 2010-07-15 |
RU2009148049A (ru) | 2011-06-27 |
US20150104483A1 (en) | 2015-04-16 |
EP2532658A1 (en) | 2012-12-12 |
EP2154135A1 (en) | 2010-02-17 |
AU2008255885A1 (en) | 2008-12-04 |
US20150105400A1 (en) | 2015-04-16 |
ES2405542T3 (es) | 2013-05-31 |
EP2154135B1 (en) | 2013-02-27 |
CA2687942A1 (en) | 2008-12-04 |
US9233969B2 (en) | 2016-01-12 |
JP5366803B2 (ja) | 2013-12-11 |
US20140350250A1 (en) | 2014-11-27 |
US8835631B2 (en) | 2014-09-16 |
BRPI0811222A2 (pt) | 2014-10-29 |
JPWO2008146753A1 (ja) | 2010-08-19 |
EP2154135A4 (en) | 2010-09-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2008146753A1 (ja) | 脳梗塞治療剤 | |
WO2010017055A3 (en) | Dihydropyridophthalazinone inhibitors of poly(adp-ribose)polymerase (parp) | |
PH12020550759A1 (en) | Compositions and methods of use of phorbol esters | |
WO2013036912A3 (en) | Amido compounds as rorϒtmodulators and uses thereof | |
WO2008006050A3 (en) | Bicyclic heteroaryl inhibitors of pde4 | |
WO2008137816A8 (en) | Tricyclic compounds as matrix metalloproteinase inhibitors | |
ATE432273T1 (de) | 3-ä4-heterocyclyl-1,2,3-triazol-1-ylü-n- arylbenzamide als inhibitoren der cytokinenproduktion für die behandlung von chronischen entzündlichen erkrankungen | |
WO2010033701A3 (en) | Inhibitors of sphingosine kinase 1 | |
GEP20125635B (en) | Inhibitors of human phosphatidyl-inositol 3-kinase delta | |
MX2012000708A (es) | Inhibidores de cinasa que regulan la señal de apoptosis. | |
WO2010142766A3 (en) | Pyrimidine derivatives as zap-70 inhibitors | |
MX345830B (es) | Compuestos a base de pirazol[1,5-a]pirimidina, composiciones que los comprenden, y metodos para su uso. | |
WO2006127525A3 (en) | Proteasome inhibitors and uses thereof | |
WO2014186313A8 (en) | Substituted bridged urea analogs as sirtuin modulators | |
WO2008138943A3 (en) | Prophylactic and therapeutic use of sirtuin inhibitors in tnf-alpha mediated pathologies | |
WO2012022681A3 (en) | Heterocyclyl pyrazolopyrimidine analogues as selective jak inhibitors | |
TW200726763A (en) | Novel compound | |
WO2009082526A3 (en) | Ortho pyrrolidine, benzyl-substituted heterocycle ccr1 antagonists for autoimmune diseases & inflammation | |
WO2006128802A3 (en) | 3-methanesulfonylquinolines as gaba-b enhancers | |
UA111520C2 (uk) | [1,2,4]триазолопіридини і їх застосування як інгібіторів фосфодіестерази | |
MX2011004870A (es) | Composicion de combinacion que comprende un inhibidor de dhodh y metotrexato para tratar enfermedades autoinmunes. | |
WO2007084542A3 (en) | Treatment of inflammatory disorders with triazole compounds | |
WO2008113756A3 (en) | Compounds having aryl-sulphonamidic structure useful as metalloproteases inhibitors | |
MX2011005971A (es) | Nuevas formas polimorficas de un derivado de azabiciclo-trifluorom etil benzamida. | |
WO2009129927A8 (en) | Compositions for the treatment of vaginal infections with chronic inflammation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200880017326.8 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08764628 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2009516304 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2687942 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12601609 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008764628 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 7450/CHENP/2009 Country of ref document: IN |
|
ENP | Entry into the national phase |
Ref document number: 20097026774 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008255885 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009148049 Country of ref document: RU |
|
ENP | Entry into the national phase |
Ref document number: 2008255885 Country of ref document: AU Date of ref document: 20080523 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: PI0811222 Country of ref document: BR Kind code of ref document: A2 Effective date: 20091124 |